Interception of Cocaine by Enzyme or Antibody Delivered with Viral Gene Transfer: A Novel Strategy for Preventing Relapse in Recovering Drug Users

Author(s): Stephen Brimijoin

Journal Name: CNS & Neurological Disorders - Drug Targets
(Formerly Current Drug Targets - CNS & Neurological Disorders)

Volume 10 , Issue 8 , 2011

Become EABM
Become Reviewer


Recent progress in enzyme engineering has led to versions of human butyrylcholinesterase (BChE) that hydrolyze cocaine efficiently in plasma, reduce concentrations reaching reward neurocircuity in the brain, and weaken behavioral responses to this drug. Along with enzyme advances, increasingly avid anti-cocaine antibodies and potent anti-cocaine vaccines have also been developed. Here we review these developments and consider the potential advantages along with the risks of delivering drug-intercepting proteins via gene transfer approaches to treat cocaine addiction.

Keywords: Adeno-associated viral vector, butyrylcholinesterase, cocain hydrolase, cocaine vaccine, gene therapy, helper-dependent viral vector, monoclonal antibody, keyhole limpet hemocyanin, hydrolytic cleavage, BChE, Cocaine, Cytomegalovirus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [880 - 891]
Pages: 12
DOI: 10.2174/187152711799219398
Price: $65

Article Metrics

PDF: 8